Suven Pharmaceuticals To Buy 67.5% Stake In Sapala Organics
Suven plans to buy the rest of Sapala after FY27, and the price will depend on how well Sapala does over the next three years
Suven Pharmaceuticals has agreed to buy a 67.5 per cent stake (equal to 51 per cent of the company) in Sapala Organics for Rs 229.5 crore in cash.
Suven, a company that makes medicine for other companies, plans to work with Sapala's current owners for a few years and then buy the whole company after FY27.
Sapala Organics in Hyderabad focuses on making Oligo drugs and nucleic acid building blocks. It made Rs 67 crore in sales in FY24 and had around 45 per cent profit. Oligo drugs are used to treat brain diseases, breathing problems, diabetic eye problems and some cancers.
Suven plans to buy the rest of Sapala after FY27, and the price will depend on how well Sapala does over the next three years. Staedmount Capital Advisors and Banyan Advisory helped Sapala with the deal.
